查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1887155

牛疫苗市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察与预测（2024-2032 年）

Bovine Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 请询问到货日

价格

牛隻疫苗市场成长驱动因素

随着畜牧业健康对全球乳製品和肉品产业的永续发展日益重要，全球牛隻疫苗市场持续稳定成长。最新数据显示，受疾病发病率上升和对预防性兽医保健日益重视的推动，预计该市场规模将在 2024 年达到 37.9 亿美元，2025 年增至 39 亿美元，并在 2032 年进一步扩大至 54.6 亿美元。北美地区在 2024 年占市场主导地位，市占率达 46.44%，主要得益于该地区乳製品消费量高、生物安全标准严格以及疫苗接种计划广泛。

牛疫苗在保护牛免受口蹄疫、出血性败血症、黑腿病和布鲁氏菌病等传染病的侵害方面发挥着至关重要的作用。世界动物卫生组织 (OIE) 的报告显示，口蹄疫影响全球 77% 的牲畜，凸显了高效疫苗接种的迫切需求。同时，乳製品需求的成长也显着推动了疫苗的普及。世界自然基金会 (WWF) 强调，全球有 2.7 亿头乳牛用于产奶，这给农民带来了沉重的负担，他们需要预防可能损害牛群生产力的疫情爆发。

市场驱动因素

牲畜疾病的日益普遍和乳製品需求的成长是关键的成长驱动因素。光是乳房炎就影响 100 头乳牛中的 30 头，由于提前淘汰和牛奶品质下降，每年造成农民高达 12,771.40 美元的损失。鑑于这些经济风险，农民优先考虑预防性疫苗接种计划，以保障其盈利能力和牲畜健康。

人们对动物福利的日益重视和农场管理实践的改进进一步加速了疫苗的普及。随着消费者对更安全、更高品质的乳製品和肉类产品的需求不断增长，生产者越来越依赖疫苗接种来降低疾病发生率并提高牲畜生产力。

市场限制因子

发展中国家疫苗接种覆盖率低仍是重大障碍。兽医基础设施匮乏、农民知识不足、经济挑战是疫苗接种率低的主要原因。根据联合国粮农组织的数据，发展中国家的牲畜死亡率仍然很高，每年有20%的反刍动物过早死亡，其中一半是由于传染病造成的。低收入地区缺乏持续的疫苗接种持续阻碍全球市场的扩张。

市场机会

研发工作正为先进疫苗技术创造机会。 2024年8月，密苏里大学研发出一种针对牛无形体病（一种严重的蜱传疾病）的疫苗。生物技术的进步，例如重组疫苗和基于基因组分析的平台，正在推动靶向疫苗的快速研发。这项创新研发流程正为控制新出现的牲畜疾病开闢新的成长途径。

市场趋势

mRNA疫苗的研发是正在改变兽用疫苗产业的新趋势。这些疫苗具有高度适应性、快速生产以及针对多种病原体的能力。 2025年2月，礼来公司与MedGene公司合作，将一种针对乳牛高致病性禽流感（HPAI）的mRNA疫苗商业化。预计这些突破将在未来十年重塑牛病预防策略。

市场区隔洞察

依产品分类

由于灭活疫苗的高效性和不断增加的核准产品，其在2024年占了最大的市场占有率。 2024年5月，勃林格殷格翰推出了BULTAVO 3，一种针对蓝舌病毒3型血清型的灭活疫苗。

依给药途径分类

2024年，肠外给药途径凭藉其高效性和快速的免疫反应，引领了市场。硕腾公司于2023年批准了针对牛支原体的Protivity疫苗，进一步巩固了该途径的领先地位。

依分销管道分类

受政府主导的大规模疫苗接种计划的推动，兽医诊所占了最大的市场占有率。印度于 2025 年启动的牲畜多重疾病疫苗接种计画 (LHDCP) 促进了以医院为基础的疫苗分发。

区域展望

北美

预计到 2024 年，北美市场规模将达到 17.6 亿美元，这主要得益于其完善的兽医基础设施和不断增长的乳製品产量。美国在该地区处于领先地位，投入大量资金进行研发，包括牛呼吸道疾病的新疫苗。

欧洲

政府主导的人畜共患病控制计画和疫苗试验，例如英国于 2023 年启动的结核病疫苗试验，正在推动市场成长。

亚太地区

由于乳製品产量不断增长和疾病负担沉重，预计亚太地区将实现强劲增长。在印度，预计到 2024 年，水牛奶产量将达到 1.107 亿吨，这将推动疫苗需求的成长。

拉丁美洲、中东和非洲

由于牲畜数量增加以及政府主导的疫苗接种工作（例如阿布达比 2024-2025 年的牲畜疫苗接种运动），预计这些地区的需求将温和增长。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 主要国家和地区牛病概况（2024 年）
  • 主要国家和地区监管状况（2024 年）
  • 牛病疫苗概况
  • 主要公司新产品发布
  • 主要产业趋势（併购、合作等）
  • 新冠疫情的影响全球牛隻疫苗市场概览

第五章 全球牛隻疫苗市场分析、洞察与预测（2019-2032）

  • 市场分析、洞察与预测：依产品分类
    • 灭活​​疫苗
    • 减毒活疫苗
    • 重组疫苗
    • 其他
  • 市场分析、洞察与预测：依给药途径分类
    • 口服
    • 注射
    • 鼻腔给药
  • 市场分析、洞察与预测：依销售管道分类
    • 兽医院
    • 兽医诊所
    • 药局
    • 其他
  • 市场分析、洞察与预测：依…区域
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美牛隻疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲牛疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚半岛
    • 欧洲其他地区

第八章亚太地区牛隻疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲牛疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲牛疫苗市场分析、洞察与预测（2019-2032）

  • 依国家/地区
    • 海湾合作委员会 (GCC)
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析 (2024)
  • 公司简介
    • 礼来动保 (Elanco)
    • 喜宝 (HIPRA)
    • 勃林格殷格翰国际有限公司 (Boehringer Ingelheim International GmbH)
    • 维克 (Virbac)
    • 默克公司 (Merck & Co., Inc.)
    • 硕腾服务有限公司 (Zoetis Services LLC)
    • 西华 (Ceva)
    • 印度免疫学有限公司 (Indian Immunologicals Ltd.)
Product Code: FBI112837

Growth Factors of bovine vaccines Market

The global bovine vaccines market continues to grow steadily as livestock health becomes increasingly important for sustaining the global dairy and meat industry. According to the latest data, the market was valued at USD 3.79 billion in 2024, is expected to rise to USD 3.90 billion in 2025, and further expand to USD 5.46 billion by 2032, supported by rising disease prevalence and increasing focus on preventive veterinary care. In 2024, North America led the market with a 46.44% share, driven by high dairy consumption, strong biosecurity standards, and extensive vaccination programs.

Bovine vaccines play a crucial role in protecting cattle from infectious diseases such as Foot and Mouth Disease (FMD), hemorrhagic septicemia, black quarter, brucellosis, and more. The World Organization for Animal Health reports that FMD affects 77% of the global livestock population, underscoring the critical need for efficient immunization. Meanwhile, rising demand for dairy products is significantly boosting vaccine adoption. The World Wildlife Fund highlights that 270 million dairy cows are raised worldwide for milk production, placing enormous pressure on farmers to prevent outbreaks that could damage herd productivity.

Market Drivers

Rising livestock disease prevalence and increasing dairy demand are the primary growth catalysts. Mastitis alone affects 30 out of every 100 cows, costing farmers up to USD 12,771.4 per year due to early culling and reduced milk quality. With such financial risks, farmers are prioritizing preventive vaccination programs to safeguard profitability and herd health.

Growing awareness of animal welfare and improved farm management practices further accelerates vaccine adoption. As consumers demand safer, higher-quality dairy and meat products, producers increasingly rely on immunization to reduce disease occurrence and enhance livestock productivity.

Market Restraints

Limited immunization uptake in developing countries remains a major obstacle. Insufficient veterinary infrastructure, lack of farmer education, and economic challenges reduce vaccination rates. According to FAO data, livestock deaths in developing nations remain high, with 20% of ruminants dying prematurely each year-half of these due to infectious diseases. The lack of consistent vaccination in low-income regions continues to restrain global market expansion.

Market Opportunities

Research and development initiatives are creating opportunities for advanced vaccine technologies. In August 2024, the University of Missouri developed a vaccine targeting bovine anaplasmosis, a devastating tick-borne disease. Biotechnology advancements, such as recombinant vaccines and genomics-based platforms, are enabling faster development of targeted immunizations. This innovation pipeline opens new growth avenues for controlling emerging livestock diseases.

Market Trends

mRNA vaccine development is an emerging trend transforming the veterinary vaccine landscape. These vaccines offer high adaptability, rapid production, and multi-pathogen targeting capabilities. In February 2025, Elanco partnered with Medgene to commercialize an mRNA-based vaccine against Highly Pathogenic Avian Influenza (HPAI) for dairy cattle. Such breakthroughs are expected to reshape bovine disease prevention strategies over the coming decade.

Segmentation Insights

By Product

In 2024, inactivated vaccines held the leading share due to high efficacy and increasing approvals. In May 2024, Boehringer Ingelheim launched BULTAVO 3, an inactivated vaccine against Bluetongue Virus Serotype 3.

By Route of Administration

The parenteral segment dominated in 2024, supported by higher efficacy and rapid immune response. Zoetis' approved Protivity vaccine for Mycoplasma bovis in 2023 reinforced the segment's leadership.

By Distribution Channel

Veterinary hospitals held the largest share due to government-led mass vaccination programs. India's 2025 LHDCP initiative to vaccinate livestock against multiple diseases boosted hospital-based vaccine distribution.

Regional Outlook

North America

The market reached USD 1.76 billion in 2024, driven by strong veterinary infrastructure and increasing dairy production. The U.S. leads the region with extensive R&D investments, including new vaccines for Bovine Respiratory Disease.

Europe

Growth is supported by government-led zoonotic disease control programs and vaccination trials, such as the U.K.'s TB vaccine study launched in 2023.

Asia Pacific

Expected to witness strong growth due to rising dairy production and high disease burden. India forecast 110.7 million metric tons of buffalo milk production in 2024, boosting vaccination requirements.

Latin America & Middle East/Africa

Moderate growth is expected, driven by rising herd populations and governmental immunization campaigns such as Abu Dhabi's 2024-2025 livestock vaccination drive.

Conclusion

With the global market expanding from USD 3.79 billion in 2024 to USD 3.90 billion in 2025, and projected to reach USD 5.46 billion by 2032, the bovine vaccines industry is set for strong long-term growth. Increasing disease prevalence, expanding dairy production, and rapid technological advancements will continue to shape the market's future.

Segmentation By Product

  • Inactivated
  • Live Attenuated
  • Recombinant
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Intranasal

By Distribution Channel

  • Veterinary Hospitals
  • Veterinary Clinics
  • Pharmacies & Drug Stores
  • Others

By Region

  • North America (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • U.S.
    • Canada
  • Europe (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of Bovine Diseases by Key Countries, By Key Countries/ Region, 2024
  • 4.2. Regulatory Scenario by Key Countries/ Region, 2024
  • 4.3. Overview of Vaccination for Bovine Diseases
  • 4.4. New Product Launches, By Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.6. Impact of COVID-19 on the Global Bovine Vaccines Market

5. Global Bovine Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Inactivated
    • 5.1.2. Live Attenuated
    • 5.1.3. Recombinant
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
    • 5.2.3. Intranasal
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Veterinary Hospitals
    • 5.3.2. Veterinary Clinics
    • 5.3.3. Pharmacies & Drug Stores
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Bovine Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Inactivated
    • 6.1.2. Live Attenuated
    • 6.1.3. Recombinant
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
    • 6.2.3. Intranasal
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Veterinary Hospitals
    • 6.3.2. Veterinary Clinics
    • 6.3.3. Pharmacies & Drug Stores
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Bovine Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Inactivated
    • 7.1.2. Live Attenuated
    • 7.1.3. Recombinant
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
    • 7.2.3. Intranasal
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Veterinary Hospitals
    • 7.3.2. Veterinary Clinics
    • 7.3.3. Pharmacies & Drug Stores
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. Germany
    • 7.4.2. U.K.
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Bovine Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Inactivated
    • 8.1.2. Live Attenuated
    • 8.1.3. Recombinant
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
    • 8.2.3. Intranasal
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Veterinary Hospitals
    • 8.3.2. Veterinary Clinics
    • 8.3.3. Pharmacies & Drug Stores
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Bovine Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Inactivated
    • 9.1.2. Live Attenuated
    • 9.1.3. Recombinant
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
    • 9.2.3. Intranasal
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Veterinary Hospitals
    • 9.3.2. Veterinary Clinics
    • 9.3.3. Pharmacies & Drug Stores
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Bovine Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Inactivated
    • 10.1.2. Live Attenuated
    • 10.1.3. Recombinant
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
    • 10.2.3. Intranasal
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Veterinary Hospitals
    • 10.3.2. Veterinary Clinics
    • 10.3.3. Pharmacies & Drug Stores
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Elanco
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. HIPRA
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Boehringer Ingelheim International GmbH
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Virbac
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Merck & Co., Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Zoetis Services LLC
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Ceva
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Indian Immunologicals Ltd.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Bovine Vaccines Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 2: Global Bovine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 3: Global Bovine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 4: Global Bovine Vaccines Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 5: North America Bovine Vaccines Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 6: North America Bovine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 7: North America Bovine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 8: North America Bovine Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 9: Europe Bovine Vaccines Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 10: Europe Bovine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 11: Europe Bovine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: Europe Bovine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Asia Pacific Bovine Vaccines Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 14: Asia Pacific Bovine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 15: Asia Pacific Bovine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 16: Asia Pacific Bovine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 17: Latin America Bovine Vaccines Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 18: Latin America Bovine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 19: Latin America Bovine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 20: Latin America Bovine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 21: Middle East & Africa Bovine Vaccines Market Revenue (USD billion) Forecast, by Product, 2019-2032
  • Table 22: Middle East & Africa Bovine Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 23: Middle East & Africa Bovine Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 24: Middle East & Africa Bovine Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Bovine Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Bovine Vaccines Market Value Share (%), by Product, 2024 & 2032
  • Figure 3: Global Bovine Vaccines Market Value Share (%), by Route of Administration, 2024 & 2032
  • Figure 4: Global Bovine Vaccines Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 5: Global Bovine Vaccines Market Value Share (%), by Region, 2024 & 2032
  • Figure 6: North America Bovine Vaccines Market Value (USD billion), by Product, 2024 & 2032
  • Figure 7: North America Bovine Vaccines Market Value Share (%), by Product, 2024
  • Figure 8: North America Bovine Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 9: North America Bovine Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 10: North America Bovine Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 11: North America Bovine Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 12: North America Bovine Vaccines Market Value (USD billion), By Country, 2024 & 2032
  • Figure 13: North America Bovine Vaccines Market Value Share (%), By Country, 2024
  • Figure 14: Europe Bovine Vaccines Market Value (USD billion), by Product, 2024 & 2032
  • Figure 15: Europe Bovine Vaccines Market Value Share (%), by Product, 2024
  • Figure 16: Europe Bovine Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 17: Europe Bovine Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 18: Europe Bovine Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 19: Europe Bovine Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 20: Europe Bovine Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 21: Europe Bovine Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 22: Asia Pacific Bovine Vaccines Market Value (USD billion), by Product, 2024 & 2032
  • Figure 23: Asia Pacific Bovine Vaccines Market Value Share (%), by Product, 2024
  • Figure 24: Asia Pacific Bovine Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 25: Asia Pacific Bovine Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 26: Asia Pacific Bovine Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 27: Asia Pacific Bovine Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 28: Asia Pacific Bovine Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 29: Asia Pacific Bovine Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 30: Latin America Bovine Vaccines Market Value (USD billion), by Product, 2024 & 2032
  • Figure 31: Latin America Bovine Vaccines Market Value Share (%), by Product, 2024
  • Figure 32: Latin America Bovine Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 33: Latin America Bovine Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 34: Latin America Bovine Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 35: Latin America Bovine Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 36: Latin America Bovine Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 37: Latin America Bovine Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 38: Middle East & Africa Bovine Vaccines Market Value (USD billion), by Product, 2024 & 2032
  • Figure 39: Middle East & Africa Bovine Vaccines Market Value Share (%), by Product, 2024
  • Figure 40: Middle East & Africa Bovine Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 41: Middle East & Africa Bovine Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 42: Middle East & Africa Bovine Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 43: Middle East & Africa Bovine Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 44: Middle East & Africa Bovine Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 45: Middle East & Africa Bovine Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 46: Global Bovine Vaccines Market Share (%), By Company, 2024